- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.05. | Intensity Therapeutics GAAP EPS of -$0.96 | 1 | Seeking Alpha | ||
| 07.05. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | 546 | PR Newswire | Cash and cash equivalents of $10.2 million as of March 31, 2026
Favorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC")... ► Artikel lesen | |
| 01.05. | Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now | 1 | Zacks | ||
| 27.03. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update | 217 | PR Newswire | Raised over $20 million in gross proceeds in 2025 and held $11.9 million in cash and cash equivalents as of December 31, 2025, with a cash runway into the second... ► Artikel lesen | |
| INTENSITY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 27.03. | Intensity Therapeutics GAAP EPS of -$8.56 misses by $0.69 | 3 | Seeking Alpha | ||
| 27.03. | INTENSITY THERAPEUTICS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 24.03. | Intensity Therapeutics erhält neues US-Patent für Krebstherapie | 3 | Investing.com Deutsch | ||
| 23.03. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.03. | Intensity Therapeutics Updates Breast Cancer Trial, Files To Resume Enrollment Following Study Pause | 3 | Benzinga.com | ||
| 12.03. | Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study | 277 | PR Newswire | Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to standard of care... ► Artikel lesen | |
| 12.03. | Intensity Therapeutics reports early trial data in breast cancer | 1 | Investing.com | ||
| 06.03. | Intensity Therapeutics erfüllt wieder NASDAQ-Anforderungen | 10 | Investing.com Deutsch | ||
| 06.03. | Intensity Therapeutics regains Nasdaq compliance | 1 | Investing.com | ||
| 06.03. | Intensity Therapeutics regains compliance with Nasdaq's minimum bid price requirement | 2 | Seeking Alpha | ||
| 06.03. | Intensity Therapeutics Inc.: Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement | 230 | PR Newswire | SHELTON, Conn., March 6, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company... ► Artikel lesen | |
| 05.03. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 5 | SEC Filings | ||
| 13.02. | Intensity Therapeutics announces 1-for-25 reverse stock split | 21 | Investing.com | ||
| 13.02. | Intensity Therapeutics kündigt Aktienzusammenlegung im Verhältnis 1:25 an | 4 | Investing.com Deutsch | ||
| 13.02. | Intensity Therapeutics Inc.: Intensity Therapeutics Announces Reverse Stock Split | 340 | PR Newswire | Intensity's common stock is expected to begin trading on a post-split adjusted basis on February 19, 2026
SHELTON, Conn., Feb. 13, 2026 /PRNewswire/ -- Intensity... ► Artikel lesen | |
| 23.01. | INTENSITY THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,20 | -0,26 % | Nabelschnurzellen aus Dresden bringen neuen Schwung in die Zelltherapie-Debatte. | ||
| NOVAVAX | 7,910 | -0,63 % | Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade | ||
| CRISPR THERAPEUTICS | 44,975 | -0,91 % | Citizens reiterates CRISPR Therapeutics stock rating on Casgevy data | ||
| EDITAS MEDICINE | 2,210 | +4,74 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| GINKGO BIOWORKS | 7,078 | -0,42 % | Ginkgo Bioworks Holdings, Inc. - 8-K, Current Report | ||
| NOVOCURE | 15,640 | +3,03 % | Novocure Reports First Quarter 2026 Financial Results | Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio
Optune Pax approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic... ► Artikel lesen | |
| TANGO THERAPEUTICS | 32,900 | 0,00 % | Starke Studiendaten: Nach 626% Kursplus in einem Jahr: Dieser Krebsspezialist macht Anleger sprachlos | © Foto: Bernd Weißbrod/dpa Ein Wirkstoff gegen die tödlichste Form von Bauchspeicheldrüsenkrebs zeigt Daten, die selbst erfahrene Onkologen aufhorchen lassen. Die Aktie reagierte entsprechend.Pankreas-Karzinom... ► Artikel lesen | |
| QIAGEN | 31,765 | -0,67 % | Qiagen-Aktie: Schlafender Riese und Übernahme-Kandidat? | Nach kurstechnisch harten Monaten kämpft sich die Aktie des niederländischen Biotechnologie- und Diagnostikunternehmens Qiagen langsam zurück. Mit Kursen um 32 Euro notiert das Papier noch immer mehr... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 42,340 | -0,05 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,130 | 0,00 % | Summit Therapeutics: CEO-Aktienkauf sorgt für Kursplus | ||
| APOGEE THERAPEUTICS | 86,18 | -0,01 % | Apogee Therapeutics, Inc. - 8-K, Current Report | ||
| TYRA BIOSCIENCES | 28,550 | 0,00 % | BofA raises Tyra Biosciences stock price target on safety outlook | ||
| DISC MEDICINE | 70,09 | 0,00 % | Disc Medicine Inc: Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria | Aligned with the FDA that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response and could potentially support a traditional approvalOn track for expected CRL response submission... ► Artikel lesen | |
| ABSCI | 7,270 | 0,00 % | Guggenheim hebt Kursziel für Absci auf 15 US-Dollar an - Potenzial durch Haarwuchsmittel | ||
| PRAXIS PRECISION MEDICINES | 264,54 | 0,00 % | Praxis Precision Medicines, Inc. - 8-K, Current Report |
INTENSITY THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,040 (-1,02 %) liegt der Kurs bei 3,890 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTENSITY THERAPEUTICS INC finden Sie auf Wallstreet Online.